Mexiletine Shortage: What Providers and Prescribers Need to Know in 2026

Mexiletine has occupied a narrow but important niche in antiarrhythmic therapy for decades. While no active national shortage is currently tracked by the FDA or ASHP as of 2026, prescribers are still fielding calls from patients who cannot fill their prescriptions. This guide provides a clinical framework for addressing mexiletine supply disruptions, counseling patients, and navigating therapeutic alternatives.

Current Supply Status (2026)

The most recent ASHP-documented shortage of mexiletine hydrochloride capsules occurred in 2020 when Teva Pharmaceuticals experienced an API procurement delay. The shortage was resolved in April 2021. As of 2026, all three strengths (150 mg, 200 mg, and 250 mg) are commercially available from multiple generic manufacturers, including Teva and Lannett.

Despite national availability, patient-level access problems persist due to:

Low prescription volume at retail pharmacies resulting in inadequate local stock

Inconsistent manufacturer-specific purchasing agreements at retail chains

Regional distribution variability

Specific strength shortfalls (e.g., 150 mg available, 200 mg backordered at a given pharmacy)

Clinical Indications and Patient Populations Affected

Patients most likely to be affected by mexiletine availability issues include:

Ventricular arrhythmia patients: Those with documented VT or frequent PVCs for whom mexiletine was selected due to its tolerability profile or use in combination with amiodarone

LQT3 patients: Long QT syndrome type 3, where mexiletine shortens the QTc and is recommended by AHA/ACC/HRS guidelines for Torsades de pointes management

Myotonic dystrophy patients: Off-label use for alleviating muscle pain and severe myotonia, per ACC/AHA/HRS guidelines

Neuropathy patients: Diabetic peripheral neuropathy where standard agents (gabapentin, duloxetine, pregabalin) have failed or are not tolerated

Therapeutic Alternatives: A Clinical Framework

Any antiarrhythmic substitution requires cardiac monitoring and individualized risk-benefit assessment. The following is a clinical summary, not a prescribing recommendation:

For Ventricular Arrhythmias

Amiodarone: Class III; broad spectrum; most potent but with extensive toxicity profile (pulmonary, hepatic, thyroid, ophthalmic). Requires ongoing laboratory monitoring. Long half-life (40-55 days) complicates transitions.

Flecainide (Class IC): Effective for ventricular ectopy in structurally normal hearts. Contraindicated post-MI and in reduced EF (CAST trial data). Use only in patients without significant structural heart disease.

Propafenone (Class IC): Similar contraindications to flecainide. Added beta-blocking effects may be beneficial or harmful depending on baseline HR.

Mexiletine + Amiodarone combination: Some guidelines support this combination for refractory VT when either drug alone is insufficient. If mexiletine is temporarily unavailable, consider whether a dose adjustment of amiodarone could bridge the gap under monitoring.

For LQT3

Mexiletine is specifically recommended by AHA/ACC/HRS for LQT3 management. There is no direct pharmacologic equivalent for this indication. In cases of true unavailability, consider hospital admission for monitoring while supply is secured, or consultation with a specialized inherited arrhythmia center. Ranolazine has been used off-label in some LQT3 cases but evidence is more limited.

Patient Counseling Recommendations

When counseling patients about mexiletine availability challenges:

Instruct them to never stop mexiletine abruptly without medical guidance, particularly if prescribed for ventricular arrhythmias.

Proactively recommend mail-order pharmacy enrollment for stable long-term patients to avoid retail stock variability.

Inform patients that medfinder can call local pharmacies on their behalf to locate available stock without requiring patients to make multiple calls themselves.

Consider maintaining a 15-30 day buffer supply for high-risk patients (LQT3, refractory VT) by optimizing their refill schedule so they always have reserve doses.

Hospital and Compounding Options

Hospital pharmacies often maintain more reliable stock of specialty antiarrhythmics than retail pharmacies. In genuine supply crises, writing a prescription to be filled at a hospital outpatient pharmacy may be the most reliable short-term solution. PCAB-accredited compounding pharmacies can also prepare mexiletine capsules from USP-grade API if commercial sources are exhausted.

medfinder offers a provider service to help your patients locate pharmacies with mexiletine in stock. For more clinical detail, see our companion guide on how to help your patients find mexiletine in stock.